CR6613A - ALTERACION DE LA EXPRESSION DE GENESIS CON ADSss PRODUCIDO IN VIVO - Google Patents

ALTERACION DE LA EXPRESSION DE GENESIS CON ADSss PRODUCIDO IN VIVO

Info

Publication number
CR6613A
CR6613A CR6613A CR6613A CR6613A CR 6613 A CR6613 A CR 6613A CR 6613 A CR6613 A CR 6613A CR 6613 A CR6613 A CR 6613A CR 6613 A CR6613 A CR 6613A
Authority
CR
Costa Rica
Prior art keywords
expression
adsss
genesis
live
changing
Prior art date
Application number
CR6613A
Other languages
English (en)
Inventor
A Conrad Charles
Chen Yin
Original Assignee
Cytogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogenix Inc filed Critical Cytogenix Inc
Publication of CR6613A publication Critical patent/CR6613A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un metodo para alterar la expresion de una secuencia de acido nucleico objetivo en una celula objetivo mediante la produccion de ADNc de una sola cadena (ADNC-ss) en la celula objetivo in vivo.
CR6613A 1999-10-04 2002-04-03 ALTERACION DE LA EXPRESSION DE GENESIS CON ADSss PRODUCIDO IN VIVO CR6613A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41156899A 1999-10-04 1999-10-04
US51470700A 2000-02-28 2000-02-28

Publications (1)

Publication Number Publication Date
CR6613A true CR6613A (es) 2004-04-21

Family

ID=27021437

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6613A CR6613A (es) 1999-10-04 2002-04-03 ALTERACION DE LA EXPRESSION DE GENESIS CON ADSss PRODUCIDO IN VIVO

Country Status (11)

Country Link
EP (1) EP1222259A1 (es)
JP (1) JP2003511025A (es)
KR (1) KR20020059608A (es)
CN (1) CN1276083C (es)
AU (1) AU7855300A (es)
BR (1) BR0014814A (es)
CA (1) CA2386246A1 (es)
CR (1) CR6613A (es)
IL (1) IL148946A0 (es)
MX (1) MXPA02003422A (es)
WO (1) WO2001025419A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419964B2 (en) 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
ATE386821T1 (de) 2000-10-23 2008-03-15 Gen Probe Inc Zusammensetzungen und methoden zur detektion von humanem immundefizienz virus 2 (hiv-2)
EP1468086A2 (en) * 2001-12-14 2004-10-20 Yale University INTRACELLULAR GENERATION OF SINGLE−STRANDED DNA
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
KR20070074574A (ko) * 2004-09-28 2007-07-12 사이토제닉, 인크. 단일-가닥 항균성 올리고뉴클레오티드 및 그의 사용
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CN102154269B (zh) * 2011-01-06 2012-05-23 湖南农业大学 基于pcr的串联重复序列快速构建法和专用引物对及应用
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
CN108396043A (zh) * 2017-02-06 2018-08-14 中国科学院上海应用物理研究所 一种5`端磷酸化单链dna的制备方法及其应用
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
JP7481755B2 (ja) * 2018-11-02 2024-05-13 ナイキジェン，リミテッド 組換えパルボウイルスベクターならびにその作製および使用方法
GB201913898D0 (en) * 2019-09-26 2019-11-13 Lightbio Ltd Nucleic acid construct
CN116286979A (zh) * 2023-03-07 2023-06-23 长沙忠健科技有限公司 一种表达逆转录酶和rna序列的质粒、细胞及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022114A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. PRODUCTION OF ssDNA $i(IN VIVO)
BR9914772A (pt) * 1998-10-09 2001-12-11 Ingene Inc Conjunto de elementos genéticos, vetor, célulahospedeira, conjunto para a produção de umasequência de ácido nucléico, método para aprodução in vivo ou in vitro de uma sequência deácido nucléico, transcrição de cdna, molécula deácido nucléico inibidor, transcrição de mrna,molécula heteroduplex e composiçãofarmacêutica

Also Published As

Publication number Publication date
MXPA02003422A (es) 2004-09-10
BR0014814A (pt) 2002-09-17
WO2001025419A1 (en) 2001-04-12
CA2386246A1 (en) 2001-04-12
JP2003511025A (ja) 2003-03-25
AU7855300A (en) 2001-05-10
CN1399679A (zh) 2003-02-26
CN1276083C (zh) 2006-09-20
EP1222259A1 (en) 2002-07-17
IL148946A0 (en) 2002-09-12
KR20020059608A (ko) 2002-07-13

Similar Documents

Publication Publication Date Title
ES2597953T3 (es) Oligorribonucleótido para inhibir la expresión de un gen predeterminado
AR031480A1 (es) Acido 3-hidroxipropionico y otros compuestos organicos
CY1106821T1 (el) Μεθοδος για την καλλιεργεια υποκαταστατου χονδρου και βιολογικη μητρα, παραγομενη συμφωνα με τη μεθοδο αυτη
MX9703063A (es) Compuestos de ester y acido boronico, su sintesis y usos.
AR024318A1 (es) Moleculas de acido nucleico del trigo, celulas de plantas transgenicas y plantas y el uso de las mismas para la produccion de almidon modificado.
ES2182897T3 (es) Regulacion por proteasoma de la actividad de nf-kappa-b.
AR027600A1 (es) Polipeptidos que tienen actividad de alfa-amilasa alcalina y los acidos nucleicos que lo codifican
BR9612258B1 (pt) inibidores de enzima conversora de interleucina-1beta, bem como composição farmacêutica.
BR9911914B1 (pt) n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
EP1085083A4 (en) CULTURAL MEDIUM FOR CULTIVATING ANIMAL CELLS AND METHOD FOR PRODUCING PROTEINS BY THE USE THEREOF
ATE335852T1 (de) Happier mapping
SV2005002082A (es) "prolina cci-779, produccion y usos de la misma, y síntesis enzimática de dos etapas de prolina cci-779 y cci-779" ref. am-101578salvo
BR0116220A (pt) Métodos para a produção de proteìnas multiméricas e composições relacionadas
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
CR9164A (es) Estabilizacion de esteres de glucocorticoides con acidos
BR9813099A (pt) Seleção positiva-negativa na recombinação homóloga
NO20020949L (no) Fettsyredesaturasegen fra planter
ES2157690T3 (es) Metodo de producir el nivel de potencia recibido en una estacion base de una red cdma y estacion base para su ejecucion.
AR069074A1 (es) Modificacion de biosintesis de lignina por supresion con acido nucleico sentido
UA94613C2 (ru) Модифицированный фермент dmo и трансгенное растение, которое его продуцирует
ES2192669T3 (es) Uso de proteinas como agentes frente a enfermedades autoinmunes.
BRPI0416637A (pt) método para produção de uma solução aquosa de etanolamina de cobre e de uma solução de monoetanolamina de cobre
DE60117566D1 (de) Erhöhte herstellung von 2-keto-l-gulonsäure
AR077315A2 (es) Plantas con caracteristicas de crecimiento modificadas y metodo para obtener las mismas
ES2167975T3 (es) Procedimiento para la preparacion de acido shikimico y sus derivados.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)